RedPath Integrated Pathology is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. Our patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. RedPath’s platform is supported by over 20 years of scientific and clinical research, and studies using it have been published in over 200 peer-reviewed journals including the New England Journal of Medicine. Two recent healthcare economic studies demonstrate that the use of PathFinderTG significantly reduces healthcare costs. Based on the strong clinical data supporting our platform, RedPath has received positive coverage decisions from Medicare and several private payers. RedPath is committed to offering cutting-edge molecular diagnostic services to support gastroenterologists, pathologists, and other physicians by improving clinical management of patients.